Pretomanid-resistant tuberculosis

•Moxifloxacin daily doses of 2400 mg were tolerated over several months.•M. tuberculosis drug resistance could be overcome by a high-dose treatment regimen.•No occurrence of cardiac AEs despite high doses of QTc interval prolonging drugs.•No eradication of M. tuberculosis despite longstanding cultur...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infection 2023-05, Vol.86 (5), p.520-524
Main Authors: Koehler, Niklas, Andres, Sönke, Merker, Matthias, Dreyer, Viola, John, Agnieszka, Kuhns, Martin, Krieger, David, Choong, Eva, Verougstraete, Nick, zur Wiesch, Pia Abel, Wicha, Sebastian G., König, Christina, Kalsdorf, Barbara, Sanchez Carballo, Patricia M., Schaub, Dagmar, Werngren, Jim, Schön, Thomas, Peloquin, Charles A., Schönfeld, Nicolas, Verstraete, Alain G., Decosterd, Laurent A., Aarnoutse, Rob, Niemann, Stefan, Maurer, Florian P., Lange, Christoph
Format: Article
Language:English
Subjects:
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Humans
Nitroimidazoles
Tuberculosis - drug therapy
Tuberculosis, Multidrug-Resistant - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c438t-165110f6bcd8fa179b0a717f4553cb4d88192980f544b85866833593dd87beac3
cites cdi_FETCH-LOGICAL-c438t-165110f6bcd8fa179b0a717f4553cb4d88192980f544b85866833593dd87beac3
container_end_page 524
container_issue 5
container_start_page 520
container_title The Journal of infection
container_volume 86
creator Koehler, Niklas
Andres, Sönke
Merker, Matthias
Dreyer, Viola
John, Agnieszka
Kuhns, Martin
Krieger, David
Choong, Eva
Verougstraete, Nick
zur Wiesch, Pia Abel
Wicha, Sebastian G.
König, Christina
Kalsdorf, Barbara
Sanchez Carballo, Patricia M.
Schaub, Dagmar
Werngren, Jim
Schön, Thomas
Peloquin, Charles A.
Schönfeld, Nicolas
Verstraete, Alain G.
Decosterd, Laurent A.
Aarnoutse, Rob
Niemann, Stefan
Maurer, Florian P.
Lange, Christoph
description •Moxifloxacin daily doses of 2400 mg were tolerated over several months.•M. tuberculosis drug resistance could be overcome by a high-dose treatment regimen.•No occurrence of cardiac AEs despite high doses of QTc interval prolonging drugs.•No eradication of M. tuberculosis despite longstanding culture conversion.•Development of pretomanid resistance on an insufficient treatment regimen.
doi_str_mv 10.1016/j.jinf.2023.01.039
format article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_DiVA_org_liu_195330</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163445323000695</els_id><sourcerecordid>2773113802</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-165110f6bcd8fa179b0a717f4553cb4d88192980f544b85866833593dd87beac3</originalsourceid><addsrcrecordid>eNp9kEtLxDAURoMozjj6B1yI7ty0JrlNmoKbYXzCgC7UbUiTVFL6GJNW8d-boaNLVxcu5zuLg9ApwSnBhF_Vae26KqWYQopJiqHYQ3PCgCY0z-g-mkcIkixjMENHIdQY4wIKfohmwHMQgtM5unj2duhb1TmTeBtcGFQ3nA9jab0emz4-jtFBpZpgT3Z3gV7vbl9WD8n66f5xtVwnOgMxJIQzQnDFS21EpUhelFjlJK8yxkCXmRGCFLQQuGJZVgomOBcArABjRF5apWGBkskbvuxmLOXGu1b5b9krJ2_c21L2_l02bpSkYAA48pcTv_H9x2jDIFsXtG0a1dl-DJLmORACItZZIDqh2vcheFv9yQmW25SyltuUcptSYiJjyjg62_nHsrXmb_LbLgLXE2BjlU9nvQza2U5b47zVgzS9-8__A9p7g1o</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2773113802</pqid></control><display><type>article</type><title>Pretomanid-resistant tuberculosis</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Koehler, Niklas ; Andres, Sönke ; Merker, Matthias ; Dreyer, Viola ; John, Agnieszka ; Kuhns, Martin ; Krieger, David ; Choong, Eva ; Verougstraete, Nick ; zur Wiesch, Pia Abel ; Wicha, Sebastian G. ; König, Christina ; Kalsdorf, Barbara ; Sanchez Carballo, Patricia M. ; Schaub, Dagmar ; Werngren, Jim ; Schön, Thomas ; Peloquin, Charles A. ; Schönfeld, Nicolas ; Verstraete, Alain G. ; Decosterd, Laurent A. ; Aarnoutse, Rob ; Niemann, Stefan ; Maurer, Florian P. ; Lange, Christoph</creator><creatorcontrib>Koehler, Niklas ; Andres, Sönke ; Merker, Matthias ; Dreyer, Viola ; John, Agnieszka ; Kuhns, Martin ; Krieger, David ; Choong, Eva ; Verougstraete, Nick ; zur Wiesch, Pia Abel ; Wicha, Sebastian G. ; König, Christina ; Kalsdorf, Barbara ; Sanchez Carballo, Patricia M. ; Schaub, Dagmar ; Werngren, Jim ; Schön, Thomas ; Peloquin, Charles A. ; Schönfeld, Nicolas ; Verstraete, Alain G. ; Decosterd, Laurent A. ; Aarnoutse, Rob ; Niemann, Stefan ; Maurer, Florian P. ; Lange, Christoph</creatorcontrib><description>•Moxifloxacin daily doses of 2400 mg were tolerated over several months.•M. tuberculosis drug resistance could be overcome by a high-dose treatment regimen.•No occurrence of cardiac AEs despite high doses of QTc interval prolonging drugs.•No eradication of M. tuberculosis despite longstanding culture conversion.•Development of pretomanid resistance on an insufficient treatment regimen.</description><identifier>ISSN: 0163-4453</identifier><identifier>ISSN: 1532-2742</identifier><identifier>EISSN: 1532-2742</identifier><identifier>DOI: 10.1016/j.jinf.2023.01.039</identifier><identifier>PMID: 36738862</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antitubercular Agents - pharmacology ; Antitubercular Agents - therapeutic use ; Humans ; Nitroimidazoles ; Tuberculosis - drug therapy ; Tuberculosis, Multidrug-Resistant - drug therapy</subject><ispartof>The Journal of infection, 2023-05, Vol.86 (5), p.520-524</ispartof><rights>2023 The British Infection Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-165110f6bcd8fa179b0a717f4553cb4d88192980f544b85866833593dd87beac3</citedby><cites>FETCH-LOGICAL-c438t-165110f6bcd8fa179b0a717f4553cb4d88192980f544b85866833593dd87beac3</cites><orcidid>0000-0003-2997-3693 ; 0000-0003-0360-8356 ; 0000-0001-6776-4978 ; 0000-0002-1911-0379 ; 0000-0002-9691-4741</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36738862$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-195330$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Koehler, Niklas</creatorcontrib><creatorcontrib>Andres, Sönke</creatorcontrib><creatorcontrib>Merker, Matthias</creatorcontrib><creatorcontrib>Dreyer, Viola</creatorcontrib><creatorcontrib>John, Agnieszka</creatorcontrib><creatorcontrib>Kuhns, Martin</creatorcontrib><creatorcontrib>Krieger, David</creatorcontrib><creatorcontrib>Choong, Eva</creatorcontrib><creatorcontrib>Verougstraete, Nick</creatorcontrib><creatorcontrib>zur Wiesch, Pia Abel</creatorcontrib><creatorcontrib>Wicha, Sebastian G.</creatorcontrib><creatorcontrib>König, Christina</creatorcontrib><creatorcontrib>Kalsdorf, Barbara</creatorcontrib><creatorcontrib>Sanchez Carballo, Patricia M.</creatorcontrib><creatorcontrib>Schaub, Dagmar</creatorcontrib><creatorcontrib>Werngren, Jim</creatorcontrib><creatorcontrib>Schön, Thomas</creatorcontrib><creatorcontrib>Peloquin, Charles A.</creatorcontrib><creatorcontrib>Schönfeld, Nicolas</creatorcontrib><creatorcontrib>Verstraete, Alain G.</creatorcontrib><creatorcontrib>Decosterd, Laurent A.</creatorcontrib><creatorcontrib>Aarnoutse, Rob</creatorcontrib><creatorcontrib>Niemann, Stefan</creatorcontrib><creatorcontrib>Maurer, Florian P.</creatorcontrib><creatorcontrib>Lange, Christoph</creatorcontrib><title>Pretomanid-resistant tuberculosis</title><title>The Journal of infection</title><addtitle>J Infect</addtitle><description>•Moxifloxacin daily doses of 2400 mg were tolerated over several months.•M. tuberculosis drug resistance could be overcome by a high-dose treatment regimen.•No occurrence of cardiac AEs despite high doses of QTc interval prolonging drugs.•No eradication of M. tuberculosis despite longstanding culture conversion.•Development of pretomanid resistance on an insufficient treatment regimen.</description><subject>Antitubercular Agents - pharmacology</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Humans</subject><subject>Nitroimidazoles</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><issn>0163-4453</issn><issn>1532-2742</issn><issn>1532-2742</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLxDAURoMozjj6B1yI7ty0JrlNmoKbYXzCgC7UbUiTVFL6GJNW8d-boaNLVxcu5zuLg9ApwSnBhF_Vae26KqWYQopJiqHYQ3PCgCY0z-g-mkcIkixjMENHIdQY4wIKfohmwHMQgtM5unj2duhb1TmTeBtcGFQ3nA9jab0emz4-jtFBpZpgT3Z3gV7vbl9WD8n66f5xtVwnOgMxJIQzQnDFS21EpUhelFjlJK8yxkCXmRGCFLQQuGJZVgomOBcArABjRF5apWGBkskbvuxmLOXGu1b5b9krJ2_c21L2_l02bpSkYAA48pcTv_H9x2jDIFsXtG0a1dl-DJLmORACItZZIDqh2vcheFv9yQmW25SyltuUcptSYiJjyjg62_nHsrXmb_LbLgLXE2BjlU9nvQza2U5b47zVgzS9-8__A9p7g1o</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Koehler, Niklas</creator><creator>Andres, Sönke</creator><creator>Merker, Matthias</creator><creator>Dreyer, Viola</creator><creator>John, Agnieszka</creator><creator>Kuhns, Martin</creator><creator>Krieger, David</creator><creator>Choong, Eva</creator><creator>Verougstraete, Nick</creator><creator>zur Wiesch, Pia Abel</creator><creator>Wicha, Sebastian G.</creator><creator>König, Christina</creator><creator>Kalsdorf, Barbara</creator><creator>Sanchez Carballo, Patricia M.</creator><creator>Schaub, Dagmar</creator><creator>Werngren, Jim</creator><creator>Schön, Thomas</creator><creator>Peloquin, Charles A.</creator><creator>Schönfeld, Nicolas</creator><creator>Verstraete, Alain G.</creator><creator>Decosterd, Laurent A.</creator><creator>Aarnoutse, Rob</creator><creator>Niemann, Stefan</creator><creator>Maurer, Florian P.</creator><creator>Lange, Christoph</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>BTSUP</scope><scope>DG8</scope><orcidid>https://orcid.org/0000-0003-2997-3693</orcidid><orcidid>https://orcid.org/0000-0003-0360-8356</orcidid><orcidid>https://orcid.org/0000-0001-6776-4978</orcidid><orcidid>https://orcid.org/0000-0002-1911-0379</orcidid><orcidid>https://orcid.org/0000-0002-9691-4741</orcidid></search><sort><creationdate>20230501</creationdate><title>Pretomanid-resistant tuberculosis</title><author>Koehler, Niklas ; Andres, Sönke ; Merker, Matthias ; Dreyer, Viola ; John, Agnieszka ; Kuhns, Martin ; Krieger, David ; Choong, Eva ; Verougstraete, Nick ; zur Wiesch, Pia Abel ; Wicha, Sebastian G. ; König, Christina ; Kalsdorf, Barbara ; Sanchez Carballo, Patricia M. ; Schaub, Dagmar ; Werngren, Jim ; Schön, Thomas ; Peloquin, Charles A. ; Schönfeld, Nicolas ; Verstraete, Alain G. ; Decosterd, Laurent A. ; Aarnoutse, Rob ; Niemann, Stefan ; Maurer, Florian P. ; Lange, Christoph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-165110f6bcd8fa179b0a717f4553cb4d88192980f544b85866833593dd87beac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antitubercular Agents - pharmacology</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Humans</topic><topic>Nitroimidazoles</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koehler, Niklas</creatorcontrib><creatorcontrib>Andres, Sönke</creatorcontrib><creatorcontrib>Merker, Matthias</creatorcontrib><creatorcontrib>Dreyer, Viola</creatorcontrib><creatorcontrib>John, Agnieszka</creatorcontrib><creatorcontrib>Kuhns, Martin</creatorcontrib><creatorcontrib>Krieger, David</creatorcontrib><creatorcontrib>Choong, Eva</creatorcontrib><creatorcontrib>Verougstraete, Nick</creatorcontrib><creatorcontrib>zur Wiesch, Pia Abel</creatorcontrib><creatorcontrib>Wicha, Sebastian G.</creatorcontrib><creatorcontrib>König, Christina</creatorcontrib><creatorcontrib>Kalsdorf, Barbara</creatorcontrib><creatorcontrib>Sanchez Carballo, Patricia M.</creatorcontrib><creatorcontrib>Schaub, Dagmar</creatorcontrib><creatorcontrib>Werngren, Jim</creatorcontrib><creatorcontrib>Schön, Thomas</creatorcontrib><creatorcontrib>Peloquin, Charles A.</creatorcontrib><creatorcontrib>Schönfeld, Nicolas</creatorcontrib><creatorcontrib>Verstraete, Alain G.</creatorcontrib><creatorcontrib>Decosterd, Laurent A.</creatorcontrib><creatorcontrib>Aarnoutse, Rob</creatorcontrib><creatorcontrib>Niemann, Stefan</creatorcontrib><creatorcontrib>Maurer, Florian P.</creatorcontrib><creatorcontrib>Lange, Christoph</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SwePub Editorial</collection><collection>SWEPUB Linköpings universitet</collection><jtitle>The Journal of infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koehler, Niklas</au><au>Andres, Sönke</au><au>Merker, Matthias</au><au>Dreyer, Viola</au><au>John, Agnieszka</au><au>Kuhns, Martin</au><au>Krieger, David</au><au>Choong, Eva</au><au>Verougstraete, Nick</au><au>zur Wiesch, Pia Abel</au><au>Wicha, Sebastian G.</au><au>König, Christina</au><au>Kalsdorf, Barbara</au><au>Sanchez Carballo, Patricia M.</au><au>Schaub, Dagmar</au><au>Werngren, Jim</au><au>Schön, Thomas</au><au>Peloquin, Charles A.</au><au>Schönfeld, Nicolas</au><au>Verstraete, Alain G.</au><au>Decosterd, Laurent A.</au><au>Aarnoutse, Rob</au><au>Niemann, Stefan</au><au>Maurer, Florian P.</au><au>Lange, Christoph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretomanid-resistant tuberculosis</atitle><jtitle>The Journal of infection</jtitle><addtitle>J Infect</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>86</volume><issue>5</issue><spage>520</spage><epage>524</epage><pages>520-524</pages><issn>0163-4453</issn><issn>1532-2742</issn><eissn>1532-2742</eissn><abstract>•Moxifloxacin daily doses of 2400 mg were tolerated over several months.•M. tuberculosis drug resistance could be overcome by a high-dose treatment regimen.•No occurrence of cardiac AEs despite high doses of QTc interval prolonging drugs.•No eradication of M. tuberculosis despite longstanding culture conversion.•Development of pretomanid resistance on an insufficient treatment regimen.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36738862</pmid><doi>10.1016/j.jinf.2023.01.039</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-2997-3693</orcidid><orcidid>https://orcid.org/0000-0003-0360-8356</orcidid><orcidid>https://orcid.org/0000-0001-6776-4978</orcidid><orcidid>https://orcid.org/0000-0002-1911-0379</orcidid><orcidid>https://orcid.org/0000-0002-9691-4741</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0163-4453
ispartof The Journal of infection, 2023-05, Vol.86 (5), p.520-524
issn 0163-4453
1532-2742
1532-2742
language eng
recordid cdi_swepub_primary_oai_DiVA_org_liu_195330
source ScienceDirect Freedom Collection 2022-2024
subjects Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Humans
Nitroimidazoles
Tuberculosis - drug therapy
Tuberculosis, Multidrug-Resistant - drug therapy
title Pretomanid-resistant tuberculosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T20%3A48%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretomanid-resistant%20tuberculosis&rft.jtitle=The%20Journal%20of%20infection&rft.au=Koehler,%20Niklas&rft.date=2023-05-01&rft.volume=86&rft.issue=5&rft.spage=520&rft.epage=524&rft.pages=520-524&rft.issn=0163-4453&rft.eissn=1532-2742&rft_id=info:doi/10.1016/j.jinf.2023.01.039&rft_dat=%3Cproquest_swepu%3E2773113802%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c438t-165110f6bcd8fa179b0a717f4553cb4d88192980f544b85866833593dd87beac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2773113802&rft_id=info:pmid/36738862&rfr_iscdi=true